Research Synthesis: Longevity Lifespan Effects

Research Synthesis: Longevity Lifespan Effects

Abstract

This paper synthesizes longevity lifespan effects as an aging-related intervention across 13 accepted source papers and 318 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct clinical evidence, 6 adjacent clinical sources, and 2 mechanistic or model-system sources, with 34 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the longevity outcome class, null signals in the contextual adjacent evidence and longevity outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that longevity lifespan effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-longevity_lifespan_effects-v06-DAILY-2026-06-05T18-08-31Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-05.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• longevity lifespan effects aging
• longevity lifespan effects older adults
• longevity lifespan effects randomized controlled trial
• longevity aging
• longevity older adults
• longevity randomized controlled trial
• lifespan aging
• lifespan older adults
• lifespan randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses longevity lifespan effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 149 records in the receipt-candidate union, 30 were classified as source candidates and 13 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	149
Classified source candidates	30
No extractable claims	43
None-only claim binding	16
Mixed partial-or-none claim-binding candidates	38
Partial-only claim-binding candidates	18
Strict high-confidence sources	4
Admitted final sources	13

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

The retained longevity lifespan effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

Longevity Outcomes

The longevity evidence packet includes 8 source-level summaries and 240 high-confidence observations. Directional coding within this packet is null=3, positive=1, unclear=4, and directness coding is indirect=5, mechanistic=2, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Representative sources: Ma 2024, Zheng 2026, ColerReilly 2025.

Contextual Adjacent Evidence Outcomes

The contextual adjacent evidence evidence packet includes 5 source-level summaries and 78 high-confidence observations. Directional coding within this packet is null=5, and directness coding is indirect=1, review=4. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Representative sources: Sensi 2026, Wong 2026, Khalil 2025.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus contains no long-term mortality randomized controlled trial in human adults. The included longevity studies rely on preclinical invertebrate models (Heath 2026; Zheng 2026; ColerReilly 2025) or large-scale observational cohorts in athletes (Altulea 2024), leaving a critical evidentiary gap between mechanistic lifespan extension and confirmed all-cause mortality benefit in general populations. IvimeyCook 2025, a vertebrate meta-analysis of rapamycin and metformin, also relies on animal data rather than human trials. Without a dedicated human mortality endpoint trial, the headline conclusion that any intervention causally extends human lifespan cannot be made; current estimates are subject to the well-documented risk that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).

Several outcome claims rest on a single source, precluding internal replication within this corpus. Single-trial evidence, even when mechanistically plausible, carries substantial risk of confounding and limits the generalizability of any claim made in this synthesis.

The population base is heavily skewed toward model organisms, limiting external validity to human aging. Ma 2024's meta-analysis covers mice, C. elegans, and Drosophila; Zheng 2026's Bacillus subtilis data come from C. elegans (median lifespan +17.48%, maximum lifespan +19.07%); and Heath 2026 tests novel tRNA synthetase inhibitors in C. elegans. No study enrolled community-dwelling older adults, medically complex patients, or underrepresented racial and ethnic groups, so the boundary conditions for lifespan effects in the general population remain uncharacterized.

Additional corpus sources included animal/preclinical evidence; the endpoint landscape is narrow: no study in this corpus measured cause-specific mortality, health-adjusted life expectancy, or quality-of-life trajectories across the lifespan. Several included papers (Wong 2026; Ho 2026; Khalil 2025; Sensi 2026) address contextual or device-related lifespan rather than biological aging, and thus contribute no evidence to the anti-aging thesis. Mechanistic autophagy markers reported by Heath 2026 in C. elegans (increased autophagic flux) are biologically informative but remain far from clinically validated surrogates for human longevity.

Conclusion

For longevity lifespan effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 13 included sources on Longevity Lifespan Effects across 2 outcome classes and 34 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 13 curated reference papers, the evidence base for Longevity Lifespan Effects shows a context-dependent profile. Positive signals appear in: longevity. Null findings dominate: contextual adjacent evidence, longevity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Longevity Lifespan Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Boominathan 2025 and IvimeyCook 2025 on longevity (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	8	null, positive, unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	0	5	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 8 indirect sources; direction profile: null, positive, unclear
P2	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 5 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Longevity Lifespan Effects should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Ma 2024; tier=B2; directness=review; endpoint=longevity; direction=unclear; representative statistic=P < 0.0001.
• Zheng 2026; tier=B2; directness=indirect; endpoint=longevity; direction=unclear.
• ColerReilly 2025; tier=B2; directness=indirect; endpoint=longevity; direction=positive; representative statistic=P < 0.01.
• IvimeyCook 2025; tier=B2; directness=indirect; endpoint=longevity; direction=null; representative statistic=P < 0.001.
• Altulea 2024; tier=B2; directness=indirect; endpoint=longevity; direction=unclear.
• Sensi 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Wong 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Goudarzi 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.02.
• Khalil 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null.
• Zou 2026; tier=B2; directness=indirect; endpoint=longevity; direction=null.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• The impact of cysteine on lifespan in three model organisms: A systematic review and meta‐analysis: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=97.
• Multi-Model Longevity Assays Reveal Lifespan- and Healthspan-Promoting Effects of Bacillus subtilis WTC019: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=55.
• Six Drivers of Aging Identified Among Genes Differentially Expressed With Age: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=25.
• Rapamycin, Not Metformin, Mirrors Dietary Restriction‐Driven Lifespan Extension in Vertebrates: A Meta‐Analysis: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=24.
• Sport and longevity: an observational study of international athletes: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=23.
• Budget impact analysis of deep brain stimulation devices with different longevity in Parkinson's disease: insights from real-world data: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23.
• A systematic review and meta-analysis of the effects of errorless motor learning on movement outcomes: a lifespan and impairment perspective: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=23.
• The Effect of Interferon Type I Adjuvant Therapy on the Lifespan and Complications of Glioma Patients Undergoing Chemotherapy: A Systematic Review and Meta‐Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=13.
• Green Environments for Sustainable Brains: Parameters Shaping Adaptive Neuroplasticity and Lifespan Neurosustainability—A Systematic Review and Future Directions: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=13.
• Prefilled versus infused regional citrate anticoagulation during continuous renal replacement therapy on circuit lifespan: protocol for a randomised controlled trial: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=11.
• The influence of attachment and relational quality on developmental outcomes across the lifespan: a systematic review and meta-analytic insights (2014–2024): outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=6.
• Novel tRNA Synthetase Inhibitors Increase Healthspan, Lifespan, and Autophagic Flux in C. elegans: outcome=longevity; directness=mechanistic; tier=C1; direction=null; claims=3.
• Estrogen-Mediated Suppression of IL-11 as a Hormonal Mechanism Underlying Female Longevity Advantage: outcome=longevity; directness=mechanistic; tier=C1; direction=unclear; claims=2.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 3 null vs positive: Boominathan 2025 vs IvimeyCook 2025; Boominathan 2025 (unclear) vs IvimeyCook 2025 (null) on longevity

• Severity 3 null vs positive: Boominathan 2025 vs Heath 2026; Boominathan 2025 (unclear) vs Heath 2026 (null) on longevity
• Severity 3 null vs positive: Boominathan 2025 vs Zou 2026; Boominathan 2025 (unclear) vs Zou 2026 (null) on longevity
• Severity 3 null vs positive: Ma 2024 vs IvimeyCook 2025; Ma 2024 (unclear) vs IvimeyCook 2025 (null) on longevity
• Severity 3 null vs positive: Ma 2024 vs Heath 2026; Ma 2024 (unclear) vs Heath 2026 (null) on longevity
• Severity 3 null vs positive: Ma 2024 vs Zou 2026; Ma 2024 (unclear) vs Zou 2026 (null) on longevity
• Severity 3 null vs positive: Altulea 2024 vs IvimeyCook 2025; Altulea 2024 (unclear) vs IvimeyCook 2025 (null) on longevity
• Severity 3 null vs positive: Altulea 2024 vs Heath 2026; Altulea 2024 (unclear) vs Heath 2026 (null) on longevity

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Schulz 2010.

References

• Ma 2024. The impact of cysteine on lifespan in three model organisms: A systematic review and meta‐analysis. Aging Cell, 2024. DOI: 10.1111/acel.14392. PMID: 39478327.
• Zheng 2026. Multi-Model Longevity Assays Reveal Lifespan-and Healthspan-Promoting Effects of Bacillus subtilis WTC019. Microorganisms, 2026. DOI: 10.3390/microorganisms14020314.
• ColerReilly 2025. Six Drivers of Aging Identified Among Genes Differentially Expressed With Age. Aging Cell, 2025. DOI: 10.1111/acel.70225. PMID: 41078088.
• IvimeyCook 2025. Rapamycin, Not Metformin, Mirrors Dietary Restriction‐Driven Lifespan Extension in Vertebrates: A Meta‐Analysis. Aging Cell, 2025. DOI: 10.1111/acel.70131. PMID: 40532901.
• Altulea 2024. Sport and longevity: an observational study of international athletes. GeroScience, 2024. DOI: 10.1007/s11357-024-01307-9. PMID: 39129051.
• Sensi 2026. Budget impact analysis of deep brain stimulation devices with different longevity in Parkinson's disease: insights from real-world data. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1735033. PMID: 41657701.
• Wong 2026. A systematic review and meta-analysis of the effects of errorless motor learning on movement outcomes: a lifespan and impairment perspective. Frontiers in Psychology, 2026. DOI: 10.3389/fpsyg.2026.1722743. PMID: 41953321.
• Khalil 2025. Green Environments for Sustainable Brains: Parameters Shaping Adaptive Neuroplasticity and Lifespan Neurosustainability—A Systematic Review and Future Directions. International Journal of Environmental Research and Public Health, 2025. DOI: 10.3390/ijerph22050690. PMID: 40427807.
• Goudarzi 2026. The Effect of Interferon Type I Adjuvant Therapy on the Lifespan and Complications of Glioma Patients Undergoing Chemotherapy: A Systematic Review and Meta‐Analysis. Cancer Reports, 2026. DOI: 10.1002/cnr2.70507. PMID: 41820027.
• Zou 2026. Prefilled versus infused regional citrate anticoagulation during continuous renal replacement therapy on circuit lifespan: protocol for a randomised controlled trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-115862. PMID: 41991269.
• Ho 2026. The influence of attachment and relational quality on developmental outcomes across the lifespan: a systematic review and meta-analytic insights (2014–2024). Frontiers in Psychology, 2026. DOI: 10.3389/fpsyg.2026.1745013. PMID: 41937813.
• Heath 2026. Novel tRNA Synthetase Inhibitors Increase Healthspan, Lifespan, and Autophagic Flux in C. elegans. Biomolecules, 2026. DOI: 10.3390/biom16010073. PMID: 41594613.
• Boominathan 2025. Estrogen-Mediated Suppression of IL-11 as a Hormonal Mechanism Underlying Female Longevity Advantage. bioRxiv preprint, 2025. DOI: 10.1101/2025.11.03.686437.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.